Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation SummitGlobeNewsWire • 09/11/24
Eliem Therapeutics: Year End 2024 MN Data With Further Potential To Unlock ValueSeeking Alpha • 06/28/24
Eliem Therapeutics Announces its Addition to the Russell 2000® and Russell 3000® IndexesGlobeNewsWire • 06/28/24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private PlacementGlobeNewsWire • 06/27/24
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Eliem Therapeutics, Inc. (ELYM) and Encourages Investors to Contact the FirmPRNewsWire • 04/15/24
ELYM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to ShareholdersBusiness Wire • 04/11/24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private PlacementGlobeNewsWire • 04/11/24
Eliem Therapeutics' stock soars 21% premarket after company says it may sell itselfMarket Watch • 07/20/23
Eliem Therapeutics Reports First Quarter Financial Results and Business HighlightsGlobeNewsWire • 05/11/23
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business HighlightsGlobeNewsWire • 03/06/23
Eliem Therapeutics Provides Strategic Update and Announces Leadership TransitionGlobeNewsWire • 02/09/23
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual ConferenceGlobeNewsWire • 11/30/22
Eliem's stock slides 20% after saying it will discontinue development of pain treatmentMarket Watch • 08/02/22
Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive DisorderGlobeNewsWire • 07/18/22